Literature DB >> 17305480

Mechanisms used by human papillomaviruses to escape the host immune response.

Shreya Kanodia1, Laura M Fahey, W Martin Kast.   

Abstract

The greatest risk factor for the development of cervical and other cancers that have been linked to the human papillomavirus (HPV) family is the persistence of the virus. To persist for the decades required to develop HPV-related cancers, the virus must escape host immunity. HPV is a simple DNA virus that has evolved to escape immune attack by a combination of stealth and interference. This review focuses on the mechanisms by which HPV can evade recognition by the host immune system.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17305480     DOI： 10.2174/156800907780006869

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN： 1568-0096            Impact factor:   3.428


  72 in total

Review 1.  HPV Vaccines: today and in the Future.

Authors:  Anna-Barbara Moscicki
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

2.  Association between human papillomavirus and chlamydia trachomatis infection risk in women: a systematic review and meta-analysis.

Authors:  Giulia Naldini; Chiara Grisci; Manuela Chiavarini; Roberto Fabiani
Journal:  Int J Public Health       Date:  2019-06-08       Impact factor: 3.380

3.  Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients.

Authors:  Liangliang Wu; Hongyu Liu; Hongchuan Guo; Qiong Wu; Songyan Yu; Yuanyuan Qin; Gang Wang; Qiyan Wu; Rong Zhang; Lingxiong Wang; Lijun Zhang; Chunxi Liu; Shunchang Jiao; Tianyi Liu
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

Review 4.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

5.  Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.

Authors:  Laura M Fahey; Adam B Raff; Diane M Da Silva; W Martin Kast
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 6.  Innate immunity against molecular mimicry: Examining galectin-mediated antimicrobial activity.

Authors:  Connie M Arthur; Seema R Patel; Amanda Mener; Nourine A Kamili; Ross M Fasano; Erin Meyer; Annie M Winkler; Martha Sola-Visner; Cassandra D Josephson; Sean R Stowell
Journal:  Bioessays       Date:  2015-12       Impact factor: 4.345

7.  Regulation of MCP-1 chemokine transcription by p53.

Authors:  Katrin Hacke; Bladimiro Rincon-Orozco; Gilles Buchwalter; Simone Y Siehler; Bohdan Wasylyk; Lisa Wiesmüller; Frank Rösl
Journal:  Mol Cancer       Date:  2010-04-20       Impact factor: 27.401

8.  Identification of a better Homo sapiens Class II HDAC inhibitor through binding energy calculations and descriptor analysis.

Authors:  Usman Sumo Friend Tambunan; Evi Kristin Wulandari
Journal:  BMC Bioinformatics       Date:  2010-10-15       Impact factor: 3.169

9.  Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.

Authors:  Janet L Brandsma; Mark Shlyankevich; Yuhua Su; Daniel Zelterman; John K Rose; Linda Buonocore
Journal:  Vaccine       Date:  2009-07-15       Impact factor: 3.641

10.  Therapeutic vaccines against human papillomavirus and cervical cancer.

Authors:  Angel Cid-Arregui
Journal:  Open Virol J       Date:  2009-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.